NEW YORK (GenomeWeb) – Trovagene today priced a public offering of about 4.4 million shares of its common stock, anticipating gross proceeds of $20 million.

The company will use the proceeds to fund its R&D work and for working capital and other general corporate purposes. The offering is expected to close on or about Feb. 11. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.